Vijaya R. Bhatt

Vijaya R. Bhatt

Hematology | Oncology

2510 Bellevue Medical Center Drive
Suite 250
Bellevue, NE 68123

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 265 publications

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 15, 2026

Adoption of an Early Enteral Nutrition Feeding Protocol in Patients Receiving an Allogeneic Stem Cell Transplant.

Adoption of an Early Enteral Nutrition Feeding Protocol in Patients Receiving an Allogeneic Stem Cell Transplant.

Journal: Nutrients

Published: March 25, 2026

Improved overall survival in acute myeloid leukemia over the last 15 years.

Improved overall survival in acute myeloid leukemia over the last 15 years.

Journal: Leukemia & lymphoma

Published: March 07, 2026

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

Journal: American journal of hematology

Published: February 19, 2026

Prognostic impact of impairments on geriatric assessment in older adults with acute myeloid leukemia.

Prognostic impact of impairments on geriatric assessment in older adults with acute myeloid leukemia.

Journal: Journal of geriatric oncology

Published: February 18, 2026

CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia.

CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia.

Journal: International journal of pharmaceutics

Published: February 09, 2026

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances

Published: September 08, 2025

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: August 22, 2025

Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.

Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.

Journal: Ecancermedicalscience

Published: July 02, 2025

Care of Older Adults with Acute Myeloid Leukemia: The Role of Geriatric Assessment.

Care of Older Adults with Acute Myeloid Leukemia: The Role of Geriatric Assessment.

Journal: Current treatment options in oncology

Published: June 24, 2025

Association between sociodemographic and clinical factors and utilization of hematopoietic cell transplant in acute myeloid leukemia from 2004 to 2020.

Association between sociodemographic and clinical factors and utilization of hematopoietic cell transplant in acute myeloid leukemia from 2004 to 2020.

Journal: Cancer epidemiology

Published: May 26, 2025

Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.

Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.

Journal: Leukemia & lymphoma

Published: April 01, 2025

Showing 1-12 of 265

Last Updated: 09/26/2026